| Autor: |
Gruson D; Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium.; Department of Clinical Biochemistry, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium., Hammerer-Lercher A; Kantonspital Aarau AG Aarau, Switzerland., Collinson P; Department of Clinical Blood Science Chemical Pathology and Cardiology, St George's University Hospitals NHS Foundation Trust, London, UK., Duff C; Department of Clinical Biochemistry, University Hospitals of North Midlands, Stoke-on-Trent, UK., Baum H; Department Laboratory Medicine, Regionale Kliniken Holding RKH, Ludwigsburg, Germany., Pulkki K; Clinical Chemistry and Hematology, Diagnostic Center, Helsinki University Hospital and the University of Helsinki, Helsinki, Finland., Suvisaari J; Clinical Chemistry and Hematology, Diagnostic Center, Helsinki University Hospital and the University of Helsinki, Helsinki, Finland., Stankovic S; Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia.; Department of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Laitinen P; Center for Medical Biochemistry, University Clinical Center of Serbia, Belgrade, Serbia., Bayes-Genis A; Germans Trias Heart Institute (iCor), Pujol, Universitat Autònoma de Barcelona; CIBERCV, Barcelona, Spain. |
| Abstrakt: |
Natriuretic peptides (NP) play an essential role in heart failure (HF) regulation, and their measurement has improved diagnostic and prognostic accuracy. Clinical symptoms and objective measurements, such as NP levels, should be included in the HF definition to render it more reliable and consistent among observers, hospitals, and healthcare systems. BNP and NT-proBNP are reasonable surrogates for cardiac disease, and their measurement is critical to early diagnosis and risk stratification of HF patients. NPs should be measured in all patients presenting with dyspnea or other symptoms suggestive of HF to facilitate early diagnosis and risk stratification. Both BNP and NT-proBNP are currently used for guided HF management and display comparable diagnostic and prognostic accuracy. Standardized cutoffs for each NP assay are essential for data comparison. The value of NP testing is recognized at various levels, including patient empowerment and education, analytical and operational issues, clinical HF management, and cost-effectiveness. |
